Introduction:
Capra Biosciences has been awarded a $7.5 million project by the BioMaP-Consortium to demonstrate the scalable manufacturing of biologically derived small molecule active pharmaceutical ingredients (APIs). Capra’s platform uses biofilm-forming microbes and proprietary bioreactors to transform low-cost feedstocks into various chemicals, including their first commercial product, retinol.
- Capra Biosciences has been awarded a $7.5 million project to demonstrate the scalability of their platform in manufacturing biologically derived small molecule APIs. They have successfully used their platform to transform low-cost feedstocks into chemicals, including retinol.
- Under the project agreement, Capra will use its bioreactor platform to manufacture three active pharmaceutical ingredients in collaboration with the U.S. Department of Health and Human Services. This will address the issue of pharmaceutical ingredient shortages.
- Capra will leverage AI design tools and modeling to rapidly design and onboard each of the APIs. They aim to demonstrate the production of these APIs at pilot scale using their modular bioreactors.
- The success of this project will showcase Capra’s technology’s potential to rapidly scale ingredients for pharmaceuticals and other applications using their modular platform and locally sourced raw materials.
- The collaboration with Next Rung Technology and their expertise in AI modeling, bioprocess scaleup, and biomanufacturing will contribute to the rapid onboarding and scaling of new products.
Conclusion:
Capra Biosciences has been awarded a $7.5 million project to demonstrate the scalability of their platform in manufacturing biologically derived small molecule APIs. This project will address the issue of pharmaceutical ingredient shortages and showcase the potential of Capra’s technology to create a broad spectrum of molecules in a highly scalable manner. Leveraging AI design tools and modeling, Capra aims to rapidly design and manufacture three active pharmaceutical ingredients using their modular bioreactors. The success of this project will provide a template for the rapid scaling of pharmaceutical ingredients and other applications using their platform and locally sourced raw materials.
